Getting in on the Gene-Editing Wave: Should You Buy CRSP Stock?
Investors who witnessed Moderna’s (Nasdaq: MRNA) meteoric rise during the pandemic know just how profitable new biotechnology companies can be. As a pioneer in gene-editing medicines, CRISPR Therapeutics (Nasdaq: CRSP) could be another up-and-coming biotech stock that you want to keep your eye on. In December 2023, CRISPR received approval from the FDA to treat…
